[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-360097-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-360097-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","ct-based-immune-radiomic-signature-for-prognosis-and-prediction-of-immunotherapy-and-anticancer-drug-response-in-nsclc","CT-based immune radiomic signature for prognosis and prediction of immunotherapy and anticancer drug response in NSCLC","","Non-small cell lung cancer (NSCLC) accounts for most lung cancers and causes high cancer-related mortality, with heterogeneous responses to immune checkpoint inhibitors, chemotherapy, and targeted therapies. Conventional immune profiling often depends on invasive biopsies and cannot capture spatial or temporal TME variation. This study develops and validates a non-invasive, immune-informed CT-based radiomic signature (CT-RadScore) to stratify prognosis and predict immunotherapy and anticancer drug responses using multi-cohort modeling and functional validation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/ct-based-immune-radiomic-signature-for-prognosis-and-prediction-of-immunotherapy-and-anticancer-drug-response-in-nsclc/360097/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/ct-based-immune-radiomic-signature-for-prognosis-and-prediction-of-immunotherapy-and-anticancer-drug-response-in-nsclc/360097.png","ImageObject",300,407,{"name":42,"@type":43},"Putri","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-19","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is an immune-informed CT-based radiomic signature needed for NSCLC?","Question",{"text":63,"@type":64},"Responses to immunotherapy, chemotherapy, and targeted therapies vary strongly across patients, and invasive tissue biopsies limit immune landscape characterization due to sampling bias and inability to capture TME heterogeneity. CT radiomics offers a non-invasive alternative, but existing signatures often lack robust biological grounding and integrated prediction across treatments.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is CT-RadScore constructed and validated in this study?",{"text":68,"@type":64},"The study integrates immune profile consensus clustering and links immune infiltration patterns to gene modules using WGCNA. CT radiomic features extracted with PyRadiomics are combined using survival models (RSF, LASSO–Cox, Elastic Net–Cox) to build CT-RadScore, which is then assessed with external validation cohorts.",{"name":70,"@type":61,"acceptedAnswer":71},"What clinical utility does CT-RadScore provide?",{"text":72,"@type":64},"CT-RadScore stratifies overall survival, where higher scores associate with worse outcomes. It also predicts immunotherapy response and relates to lower TIDE scores, and it correlates with sensitivity to agents such as paclitaxel, gefitinib, and carboplatin.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},360097,1790870205,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962085571259,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","TYPE Original Research PUBLISHED 29 April 2026  \nDOI 10.3389/fimmu.2026.1767389  \nOPEN ACCESS  \nEDITED BY  \nAlessio Campisi,  \nUniversität Heidelberg, Germany  \nREVIEWED BY  \nShiyang Lv,  \nFudan University Shanghai Cancer Center, China  \nJj Z.,  \nAnhui Medical University, China  \n*CORRESPONDENCE  \nJianying Ma  \n[jianying. ma.research@gmail.com](jianying. ma.research@gmail.com)[ ](jianying. ma.research@gmail.com)Yunping Geng  \n [hgang516@163.com](hgang516@163.com)[ ](hgang516@163.com)Jiawei Guo  \n [guojw9@alumni.sysu.edu.cn](guojw9@alumni.sysu.edu.cn)  \n†These authors have contributed equally to this work  \nRECEIVED 14 December 2025  \nREVISED 21 March 2026  \nACCEPTED 10 April 2026  \nPUBLISHED 29 April 2026  \nCITATION  \nMa J, Guo K, Gao Y, Li T, Li F, Pang C, Geng Y and Guo J (2026) CT-based immune radiomic signature for prognosis and prediction of immunotherapy and anticancer drug response in NSCLC.  \nFront. Immunol. 17:1767389 .  \ndoi: 10.3389/fimmu.2026.1767389  \nCOPYRIGHT  \n© 2026 Ma, Guo, Gao, Li, Li, Pang, Geng and Guo. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nCT-based immune radiomic signature for prognosis and prediction of immunotherapy and anticancer drug response in NSCLC  \nJianying Ma 1*†, Kaixing Guo 2†, Yanpo Gao 3, Tengfei Li 1, Fei Li 1, Chaoqi Pang 3, Yunping Geng 1* and Jiawei Guo 4*  \n1 Department of CT Imaging, Nanyang Central Hospital, Nanyang, China, 2 Department of Pharmacy, Afﬁliated Hospital of Hebei University of Engineering, Handan, China, 3 Department of Medicine and Health, Handan Vocational College of Science and Technology, Handan, China, 4 Department of Pharmacology, School of Medicine, Yangtze University, Jingzhou, China  \nBackground: Non-small cell lung cancer (NSCLC) accounts for more than 85% of lung cancers and remains the leading cause of cancer-related mortality worldwide, with dismal prognosis and pronounced inter-patient heterogeneity in responses to immune checkpoint inhibitors, chemotherapy and targeted therapies. Current approaches to characterising the tumour microenvironment (TME) immune landscape rely on invasive tissue biopsies, which are constrained by sampling bias and an inability to capture spatial and temporal heterogeneity. CT-based radiomics, which derives high-dimensional quantitative features from routine imaging, offers a non-invasive alternative; however, most existing radiomic signatures lack robust biological grounding and do not provide integrated prediction of multiple treatment responses.  \nObjective: To develop and validate a non-invasive, immune-informed CT-based radiomic signature (CT-RadScore) that reﬂects TME immune phenotypes and to evaluate its utility for prognostic stratiﬁcation and prediction of responses to immunotherapy and anticancer drugs in NSCLC.  \nMethods: We analysed multiple NSCLC cohorts, including TCIA NSCLC Radiogenomics, TCGA LUAD+LUSC and an in-house cohort from Nanyang Central Hospital. Consensus clustering of immune proﬁles was used to derive immune subtypes, and weighted gene co-expression network analysis (WGCNA) linked immune inﬁltration patterns to gene modules. CT radiomic features were extracted using PyRadiomics, and machine-learning survival models (random survival forest [RSF], LASSO–Cox, Elastic Net–Cox) were compared to construct CT-RadScore. Functional validation included Tumour Immune Dysfunction and Exclusion (TIDE) analysis, Tracking Tumour Immunophenotype (TIP) proﬁling, insilico drug sensitivity prediction, single-cell RNA sequencing (scRNA-seq) and GPX2 knockdown experiments.  \nResults: Consensus clustering identiﬁed ","cbCailqmsactofVI","https://ap.wps.com/l/cbCailqmsactofVI","pdf",14826656,15,"English","# Introduction\n# Objective\n# Methods\n# Results\n# Conclusion","[{\"question\":\"Why is an immune-informed CT-based radiomic signature needed for NSCLC?\",\"answer\":\"Responses to immunotherapy, chemotherapy, and targeted therapies vary strongly across patients, and invasive tissue biopsies limit immune landscape characterization due to sampling bias and inability to capture TME heterogeneity. CT radiomics offers a non-invasive alternative, but existing signatures often lack robust biological grounding and integrated prediction across treatments.\"},{\"question\":\"How is CT-RadScore constructed and validated in this study?\",\"answer\":\"The study integrates immune profile consensus clustering and links immune infiltration patterns to gene modules using WGCNA. CT radiomic features extracted with PyRadiomics are combined using survival models (RSF, LASSO–Cox, Elastic Net–Cox) to build CT-RadScore, which is then assessed with external validation cohorts.\"},{\"question\":\"What clinical utility does CT-RadScore provide?\",\"answer\":\"CT-RadScore stratifies overall survival, where higher scores associate with worse outcomes. It also predicts immunotherapy response and relates to lower TIDE scores, and it correlates with sensitivity to agents such as paclitaxel, gefitinib, and carboplatin.\"}]","CT-based immune radiomic signature for prognosis and prediction of immunotherapy and anticancer drug response in NSCLC | PDF",1790138742,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/266385708343a2676c27d7527776bb4f.webp",983,1389,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2e0510b17b0dda16fb354549f5ce8720.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3328f075fc4fd036fbe0cd3e5e9ab4da.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/94c667732102157fd575cb9c66d458a6.webp",980,1385]